Meeting
2021 ASCO Annual Meeting
A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.
Authors
Pierangela Sepe
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Pierangela Sepe , Giuseppe Procopio , Umberto Basso , Orazio Caffo , Vera Cappelletti , Melanie Claps , Ugo De Giorgi , Lucia Fratino , Valentina Guadalupi , Patrizia Miodini , Bruno Perrucci , Alessia Mennitto , Daniele Santini , Francesco Spina , Arianna Ottini , Filippo G. De Braud , Elena Verzoni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03103724
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5052)
DOI
10.1200/JCO.2021.39.15_suppl.5052
Abstract #
5052
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
First Author: Louise Emmett
Poster
2020 ASCO Virtual Scientific Program
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).
First Author: Johann S. De Bono
Poster
2020 ASCO Virtual Scientific Program
CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith
Poster
2019 ASCO Annual Meeting
Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.
First Author: Syed A. Hussain